Trial Profile
Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Vitamin K antagonists
- Indications Stroke; Transient ischaemic attacks
- Focus Adverse reactions
- Acronyms PRODAST
- 09 May 2022 Status changed from active, no longer recruiting to completed.
- 29 Sep 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2021.
- 02 Dec 2020 Status changed from recruiting to active, no longer recruiting.